nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—Docetaxel—pancreatic cancer	0.517	0.789	CbGbCtD
Rasagiline—CYP1A2—Dacarbazine—pancreatic cancer	0.0451	0.0689	CbGbCtD
Rasagiline—CYP1A2—Tamoxifen—pancreatic cancer	0.0359	0.0548	CbGbCtD
Rasagiline—CYP1A2—Erlotinib—pancreatic cancer	0.0305	0.0466	CbGbCtD
Rasagiline—CYP1A2—Fluorouracil—pancreatic cancer	0.0265	0.0404	CbGbCtD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CCND1—pancreatic cancer	0.000291	0.00222	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—MYC—pancreatic cancer	0.000291	0.00221	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—pancreatic cancer	0.000288	0.00219	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—TP53—pancreatic cancer	0.000288	0.00219	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—TGFB1—pancreatic cancer	0.000285	0.00217	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—STAT3—pancreatic cancer	0.000285	0.00217	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—NRAS—pancreatic cancer	0.000284	0.00216	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—STK11—pancreatic cancer	0.000277	0.00211	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—SRC—pancreatic cancer	0.000275	0.00209	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CDKN2A—pancreatic cancer	0.000274	0.00209	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN2A—pancreatic cancer	0.000274	0.00209	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CG—pancreatic cancer	0.000274	0.00209	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—TNF—pancreatic cancer	0.000271	0.00206	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—STAT3—pancreatic cancer	0.000265	0.00202	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—MYC—pancreatic cancer	0.000264	0.00201	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—RB1—pancreatic cancer	0.000261	0.00199	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CDKN2A—pancreatic cancer	0.000257	0.00196	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—PTGS2—pancreatic cancer	0.000256	0.00195	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—TP53—pancreatic cancer	0.000256	0.00195	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—BCL2L1—pancreatic cancer	0.000255	0.00195	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—HRAS—pancreatic cancer	0.000254	0.00193	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—TSC2—pancreatic cancer	0.000254	0.00193	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	0.000251	0.00191	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—AKT1—pancreatic cancer	0.000248	0.00189	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—HRAS—pancreatic cancer	0.000245	0.00186	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—KRAS—pancreatic cancer	0.000244	0.00186	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—AKT1—pancreatic cancer	0.000243	0.00185	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	0.000243	0.00185	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CD—pancreatic cancer	0.000241	0.00183	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TSC2—pancreatic cancer	0.000239	0.00182	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TYMS—pancreatic cancer	0.000238	0.00181	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MET—pancreatic cancer	0.000238	0.00181	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CASP3—pancreatic cancer	0.000238	0.00181	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—TNF—pancreatic cancer	0.000236	0.0018	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—BCL2L1—pancreatic cancer	0.000236	0.00179	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—PIK3CA—pancreatic cancer	0.000235	0.00179	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—MYC—pancreatic cancer	0.000234	0.00178	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—AKT1—pancreatic cancer	0.000233	0.00178	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CCND1—pancreatic cancer	0.000231	0.00176	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CXCL8—pancreatic cancer	0.000231	0.00176	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN2A—pancreatic cancer	0.000229	0.00175	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—PIK3CA—pancreatic cancer	0.000224	0.00171	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—HRAS—pancreatic cancer	0.000224	0.00171	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFNA5—pancreatic cancer	0.000224	0.00171	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—AKT1—pancreatic cancer	0.000224	0.00171	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CASP3—pancreatic cancer	0.000223	0.0017	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN2A—pancreatic cancer	0.000222	0.00169	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CASP3—pancreatic cancer	0.000221	0.00168	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—DTX4—pancreatic cancer	0.000218	0.00166	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—HRAS—pancreatic cancer	0.000217	0.00166	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—AKT1—pancreatic cancer	0.000216	0.00165	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—AKT1—pancreatic cancer	0.000216	0.00165	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CTNNB1—pancreatic cancer	0.000213	0.00162	CbGpPWpGaD
Rasagiline—CYP1A2—Estrogen Receptor Pathway—STAT3—pancreatic cancer	0.000212	0.00161	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CB—pancreatic cancer	0.00021	0.0016	CbGpPWpGaD
Rasagiline—CYP1A2—Melatonin metabolism and effects—APOE—pancreatic cancer	0.000209	0.00159	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CXCL8—pancreatic cancer	0.000208	0.00158	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—HRAS—pancreatic cancer	0.000208	0.00158	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—RB1—pancreatic cancer	0.000207	0.00158	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—AKT1—pancreatic cancer	0.000201	0.00153	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—NRAS—pancreatic cancer	0.000199	0.00152	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MMP2—pancreatic cancer	0.000199	0.00151	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—AKT1—pancreatic cancer	0.000198	0.00151	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—RB1—pancreatic cancer	0.000195	0.00148	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CDH1—pancreatic cancer	0.000194	0.00148	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—HRAS—pancreatic cancer	0.000193	0.00147	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—AKT1—pancreatic cancer	0.000192	0.00146	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—KDR—pancreatic cancer	0.000191	0.00145	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CDH1—pancreatic cancer	0.00019	0.00145	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CCND1—pancreatic cancer	0.000188	0.00143	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—PTEN—pancreatic cancer	0.000187	0.00142	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—MET—pancreatic cancer	0.000187	0.00142	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CTNNB1—pancreatic cancer	0.000186	0.00142	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MYC—pancreatic cancer	0.000186	0.00141	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—MYC—pancreatic cancer	0.000186	0.00141	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PTEN—pancreatic cancer	0.000181	0.00138	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	0.000181	0.00138	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RAP1GAP—pancreatic cancer	0.000178	0.00136	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—pancreatic cancer	0.000176	0.00134	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CG—pancreatic cancer	0.000176	0.00134	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—AKT1—pancreatic cancer	0.000176	0.00134	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—EGF—pancreatic cancer	0.000174	0.00132	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—SRC—pancreatic cancer	0.000173	0.00132	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—pancreatic cancer	0.000173	0.00132	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	0.000173	0.00132	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—TGFB1—pancreatic cancer	0.000172	0.00131	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—KRAS—pancreatic cancer	0.000172	0.00131	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—AKT1—pancreatic cancer	0.000171	0.0013	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—NRAS—pancreatic cancer	0.000162	0.00123	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	0.00016	0.00122	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TGFB1—pancreatic cancer	0.000155	0.00118	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CD—pancreatic cancer	0.000154	0.00118	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—pancreatic cancer	0.000152	0.00116	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MYC—pancreatic cancer	0.000151	0.00115	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TGFB1—pancreatic cancer	0.00015	0.00115	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CASP3—pancreatic cancer	0.000149	0.00113	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—PTEN—pancreatic cancer	0.000148	0.00113	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—HRAS—pancreatic cancer	0.000146	0.00111	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CASP3—pancreatic cancer	0.000146	0.00111	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CCND1—pancreatic cancer	0.000145	0.0011	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CTNNB1—pancreatic cancer	0.000143	0.00109	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—pancreatic cancer	0.000143	0.00109	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CTNNB1—pancreatic cancer	0.00014	0.00107	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—PTEN—pancreatic cancer	0.00014	0.00106	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—KRAS—pancreatic cancer	0.000139	0.00106	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CB—pancreatic cancer	0.000135	0.00103	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PRSS1—pancreatic cancer	0.000133	0.00101	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	0.000133	0.00101	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA5—pancreatic cancer	0.000131	0.000995	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—AKT1—pancreatic cancer	0.000129	0.000981	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CA—pancreatic cancer	0.000128	0.000975	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—pancreatic cancer	0.000128	0.000971	CbGpPWpGaD
Rasagiline—BCL2—Immune System—DTX4—pancreatic cancer	0.000127	0.000966	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—VEGFA—pancreatic cancer	0.000126	0.000961	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—pancreatic cancer	0.000124	0.000943	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PPP2R5B—pancreatic cancer	0.000123	0.00094	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	0.000123	0.000939	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFNA1—pancreatic cancer	0.000123	0.000936	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—HRAS—pancreatic cancer	0.000122	0.000929	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—EGFR—pancreatic cancer	0.000121	0.000919	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CCND1—pancreatic cancer	0.00012	0.000918	CbGpPWpGaD
Rasagiline—Body temperature increased—Irinotecan—pancreatic cancer	0.00012	0.000563	CcSEcCtD
Rasagiline—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00012	0.000562	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—RB1—pancreatic cancer	0.00012	0.000916	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	0.00012	0.000914	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—AKT1—pancreatic cancer	0.00012	0.000912	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CTNNB1—pancreatic cancer	0.000119	0.000909	CbGpPWpGaD
Rasagiline—Anaemia—Docetaxel—pancreatic cancer	0.000119	0.000558	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	0.000119	0.000905	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—HRAS—pancreatic cancer	0.000118	0.000902	CbGpPWpGaD
Rasagiline—Muscular weakness—Doxorubicin—pancreatic cancer	0.000118	0.000551	CcSEcCtD
Rasagiline—Vomiting—Sunitinib—pancreatic cancer	0.000118	0.00055	CcSEcCtD
Rasagiline—Body temperature increased—Gemcitabine—pancreatic cancer	0.000117	0.000549	CcSEcCtD
Rasagiline—Dysuria—Epirubicin—pancreatic cancer	0.000117	0.000546	CcSEcCtD
Rasagiline—Rash—Sunitinib—pancreatic cancer	0.000117	0.000545	CcSEcCtD
Rasagiline—Dermatitis—Sunitinib—pancreatic cancer	0.000117	0.000545	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—PTEN—pancreatic cancer	0.000116	0.000886	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MYC—pancreatic cancer	0.000116	0.000885	CbGpPWpGaD
Rasagiline—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000116	0.000543	CcSEcCtD
Rasagiline—Urticaria—Fluorouracil—pancreatic cancer	0.000116	0.000542	CcSEcCtD
Rasagiline—Headache—Sunitinib—pancreatic cancer	0.000116	0.000542	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	0.000116	0.000882	CbGpPWpGaD
Rasagiline—Syncope—Docetaxel—pancreatic cancer	0.000116	0.000541	CcSEcCtD
Rasagiline—Dysphagia—Doxorubicin—pancreatic cancer	0.000116	0.00054	CcSEcCtD
Rasagiline—Influenza—Doxorubicin—pancreatic cancer	0.000116	0.00054	CcSEcCtD
Rasagiline—Asthma—Doxorubicin—pancreatic cancer	0.000116	0.00054	CcSEcCtD
Rasagiline—Leukopenia—Docetaxel—pancreatic cancer	0.000116	0.00054	CcSEcCtD
Rasagiline—MAOB—Metabolism—ARG2—pancreatic cancer	0.000115	0.00088	CbGpPWpGaD
Rasagiline—Pollakiuria—Epirubicin—pancreatic cancer	0.000115	0.00054	CcSEcCtD
Rasagiline—Body temperature increased—Fluorouracil—pancreatic cancer	0.000115	0.000539	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—IFNA2—pancreatic cancer	0.000114	0.000871	CbGpPWpGaD
Rasagiline—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000114	0.000533	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EGFR—pancreatic cancer	0.000114	0.000865	CbGpPWpGaD
Rasagiline—Loss of consciousness—Docetaxel—pancreatic cancer	0.000113	0.00053	CcSEcCtD
Rasagiline—Weight decreased—Epirubicin—pancreatic cancer	0.000113	0.000528	CcSEcCtD
Rasagiline—Cough—Docetaxel—pancreatic cancer	0.000113	0.000527	CcSEcCtD
Rasagiline—Angina pectoris—Doxorubicin—pancreatic cancer	0.000113	0.000526	CcSEcCtD
Rasagiline—Hypersensitivity—Irinotecan—pancreatic cancer	0.000112	0.000525	CcSEcCtD
Rasagiline—Convulsion—Docetaxel—pancreatic cancer	0.000112	0.000523	CcSEcCtD
Rasagiline—Hypertension—Docetaxel—pancreatic cancer	0.000111	0.000521	CcSEcCtD
Rasagiline—Infestation NOS—Epirubicin—pancreatic cancer	0.000111	0.000521	CcSEcCtD
Rasagiline—Infestation—Epirubicin—pancreatic cancer	0.000111	0.000521	CcSEcCtD
Rasagiline—Arthralgia—Docetaxel—pancreatic cancer	0.00011	0.000514	CcSEcCtD
Rasagiline—Chest pain—Docetaxel—pancreatic cancer	0.00011	0.000514	CcSEcCtD
Rasagiline—Nausea—Sunitinib—pancreatic cancer	0.00011	0.000514	CcSEcCtD
Rasagiline—Asthenia—Irinotecan—pancreatic cancer	0.000109	0.000511	CcSEcCtD
Rasagiline—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000109	0.00051	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000109	0.00051	CcSEcCtD
Rasagiline—Stomatitis—Epirubicin—pancreatic cancer	0.000109	0.000508	CcSEcCtD
Rasagiline—Jaundice—Epirubicin—pancreatic cancer	0.000109	0.000508	CcSEcCtD
Rasagiline—Conjunctivitis—Epirubicin—pancreatic cancer	0.000108	0.000506	CcSEcCtD
Rasagiline—Dysuria—Doxorubicin—pancreatic cancer	0.000108	0.000505	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—SRC—pancreatic cancer	0.000108	0.000821	CbGpPWpGaD
Rasagiline—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000108	0.000503	CcSEcCtD
Rasagiline—Dry mouth—Docetaxel—pancreatic cancer	0.000107	0.000502	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000107	0.000502	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	0.000107	0.000818	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—pancreatic cancer	0.000107	0.000817	CbGpPWpGaD
Rasagiline—Sweating—Epirubicin—pancreatic cancer	0.000107	0.000499	CcSEcCtD
Rasagiline—Pollakiuria—Doxorubicin—pancreatic cancer	0.000107	0.000499	CcSEcCtD
Rasagiline—Asthenia—Gemcitabine—pancreatic cancer	0.000107	0.000498	CcSEcCtD
Rasagiline—Haematuria—Epirubicin—pancreatic cancer	0.000106	0.000497	CcSEcCtD
Rasagiline—Confusional state—Docetaxel—pancreatic cancer	0.000106	0.000497	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TNF—pancreatic cancer	0.000106	0.000807	CbGpPWpGaD
Rasagiline—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000106	0.000493	CcSEcCtD
Rasagiline—Epistaxis—Epirubicin—pancreatic cancer	0.000105	0.000491	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—VEGFA—pancreatic cancer	0.000105	0.0008	CbGpPWpGaD
Rasagiline—Pruritus—Gemcitabine—pancreatic cancer	0.000105	0.000491	CcSEcCtD
Rasagiline—Infection—Docetaxel—pancreatic cancer	0.000105	0.000489	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	0.000105	0.000797	CbGpPWpGaD
Rasagiline—Weight decreased—Doxorubicin—pancreatic cancer	0.000105	0.000489	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—AKT1—pancreatic cancer	0.000105	0.000796	CbGpPWpGaD
Rasagiline—Diarrhoea—Irinotecan—pancreatic cancer	0.000104	0.000487	CcSEcCtD
Rasagiline—Shock—Docetaxel—pancreatic cancer	0.000104	0.000484	CcSEcCtD
Rasagiline—Nervous system disorder—Docetaxel—pancreatic cancer	0.000103	0.000483	CcSEcCtD
Rasagiline—Pruritus—Fluorouracil—pancreatic cancer	0.000103	0.000483	CcSEcCtD
Rasagiline—Infestation NOS—Doxorubicin—pancreatic cancer	0.000103	0.000482	CcSEcCtD
Rasagiline—Infestation—Doxorubicin—pancreatic cancer	0.000103	0.000482	CcSEcCtD
Rasagiline—Skin disorder—Docetaxel—pancreatic cancer	0.000102	0.000478	CcSEcCtD
Rasagiline—Diarrhoea—Gemcitabine—pancreatic cancer	0.000102	0.000475	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—TP53—pancreatic cancer	0.000101	0.000772	CbGpPWpGaD
Rasagiline—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000101	0.000472	CcSEcCtD
Rasagiline—MAOB—Metabolism—TYMP—pancreatic cancer	0.000101	0.000769	CbGpPWpGaD
Rasagiline—Dizziness—Irinotecan—pancreatic cancer	0.000101	0.000471	CcSEcCtD
Rasagiline—Haemoglobin—Epirubicin—pancreatic cancer	0.000101	0.00047	CcSEcCtD
Rasagiline—Jaundice—Doxorubicin—pancreatic cancer	0.0001	0.00047	CcSEcCtD
Rasagiline—Stomatitis—Doxorubicin—pancreatic cancer	0.0001	0.00047	CcSEcCtD
Rasagiline—Anorexia—Docetaxel—pancreatic cancer	0.0001	0.000469	CcSEcCtD
Rasagiline—Rhinitis—Epirubicin—pancreatic cancer	0.0001	0.000469	CcSEcCtD
Rasagiline—Conjunctivitis—Doxorubicin—pancreatic cancer	0.0001	0.000468	CcSEcCtD
Rasagiline—Haemorrhage—Epirubicin—pancreatic cancer	0.0001	0.000467	CcSEcCtD
Rasagiline—Diarrhoea—Fluorouracil—pancreatic cancer	9.99e-05	0.000467	CcSEcCtD
Rasagiline—Hypoaesthesia—Epirubicin—pancreatic cancer	9.95e-05	0.000465	CcSEcCtD
Rasagiline—Sweating—Doxorubicin—pancreatic cancer	9.88e-05	0.000462	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—pancreatic cancer	9.88e-05	0.000752	CbGpPWpGaD
Rasagiline—Urinary tract disorder—Epirubicin—pancreatic cancer	9.88e-05	0.000462	CcSEcCtD
Rasagiline—Oedema peripheral—Epirubicin—pancreatic cancer	9.85e-05	0.000461	CcSEcCtD
Rasagiline—Hypotension—Docetaxel—pancreatic cancer	9.84e-05	0.00046	CcSEcCtD
Rasagiline—Haematuria—Doxorubicin—pancreatic cancer	9.83e-05	0.000459	CcSEcCtD
Rasagiline—Connective tissue disorder—Epirubicin—pancreatic cancer	9.83e-05	0.000459	CcSEcCtD
Rasagiline—Urethral disorder—Epirubicin—pancreatic cancer	9.8e-05	0.000458	CcSEcCtD
Rasagiline—Epistaxis—Doxorubicin—pancreatic cancer	9.72e-05	0.000454	CcSEcCtD
Rasagiline—Vomiting—Irinotecan—pancreatic cancer	9.69e-05	0.000453	CcSEcCtD
Rasagiline—Dizziness—Fluorouracil—pancreatic cancer	9.65e-05	0.000451	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	9.62e-05	0.000733	CbGpPWpGaD
Rasagiline—Rash—Irinotecan—pancreatic cancer	9.61e-05	0.000449	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	9.6e-05	0.000731	CbGpPWpGaD
Rasagiline—Dermatitis—Irinotecan—pancreatic cancer	9.6e-05	0.000449	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	9.6e-05	0.000449	CcSEcCtD
Rasagiline—Headache—Irinotecan—pancreatic cancer	9.55e-05	0.000446	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—pancreatic cancer	9.54e-05	0.000726	CbGpPWpGaD
Rasagiline—Insomnia—Docetaxel—pancreatic cancer	9.53e-05	0.000445	CcSEcCtD
Rasagiline—Paraesthesia—Docetaxel—pancreatic cancer	9.46e-05	0.000442	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—EGFR—pancreatic cancer	9.45e-05	0.00072	CbGpPWpGaD
Rasagiline—Vomiting—Gemcitabine—pancreatic cancer	9.44e-05	0.000441	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	9.41e-05	0.000717	CbGpPWpGaD
Rasagiline—Dyspnoea—Docetaxel—pancreatic cancer	9.39e-05	0.000439	CcSEcCtD
Rasagiline—Somnolence—Docetaxel—pancreatic cancer	9.37e-05	0.000438	CcSEcCtD
Rasagiline—Rash—Gemcitabine—pancreatic cancer	9.36e-05	0.000438	CcSEcCtD
Rasagiline—Dermatitis—Gemcitabine—pancreatic cancer	9.35e-05	0.000437	CcSEcCtD
Rasagiline—Eye disorder—Epirubicin—pancreatic cancer	9.35e-05	0.000437	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—pancreatic cancer	9.34e-05	0.000711	CbGpPWpGaD
Rasagiline—Haemoglobin—Doxorubicin—pancreatic cancer	9.3e-05	0.000435	CcSEcCtD
Rasagiline—Headache—Gemcitabine—pancreatic cancer	9.3e-05	0.000435	CcSEcCtD
Rasagiline—Cardiac disorder—Epirubicin—pancreatic cancer	9.28e-05	0.000434	CcSEcCtD
Rasagiline—Vomiting—Fluorouracil—pancreatic cancer	9.28e-05	0.000434	CcSEcCtD
Rasagiline—Rhinitis—Doxorubicin—pancreatic cancer	9.28e-05	0.000434	CcSEcCtD
Rasagiline—Dyspepsia—Docetaxel—pancreatic cancer	9.27e-05	0.000433	CcSEcCtD
Rasagiline—Haemorrhage—Doxorubicin—pancreatic cancer	9.25e-05	0.000433	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGS2—pancreatic cancer	9.24e-05	0.000704	CbGpPWpGaD
Rasagiline—Hypoaesthesia—Doxorubicin—pancreatic cancer	9.21e-05	0.00043	CcSEcCtD
Rasagiline—Rash—Fluorouracil—pancreatic cancer	9.2e-05	0.00043	CcSEcCtD
Rasagiline—Dermatitis—Fluorouracil—pancreatic cancer	9.19e-05	0.00043	CcSEcCtD
Rasagiline—Decreased appetite—Docetaxel—pancreatic cancer	9.16e-05	0.000428	CcSEcCtD
Rasagiline—Headache—Fluorouracil—pancreatic cancer	9.14e-05	0.000427	CcSEcCtD
Rasagiline—Urinary tract disorder—Doxorubicin—pancreatic cancer	9.14e-05	0.000427	CcSEcCtD
Rasagiline—Oedema peripheral—Doxorubicin—pancreatic cancer	9.12e-05	0.000426	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Docetaxel—pancreatic cancer	9.09e-05	0.000425	CcSEcCtD
Rasagiline—Connective tissue disorder—Doxorubicin—pancreatic cancer	9.09e-05	0.000425	CcSEcCtD
Rasagiline—Angiopathy—Epirubicin—pancreatic cancer	9.07e-05	0.000424	CcSEcCtD
Rasagiline—Urethral disorder—Doxorubicin—pancreatic cancer	9.07e-05	0.000424	CcSEcCtD
Rasagiline—Nausea—Irinotecan—pancreatic cancer	9.05e-05	0.000423	CcSEcCtD
Rasagiline—Immune system disorder—Epirubicin—pancreatic cancer	9.03e-05	0.000422	CcSEcCtD
Rasagiline—Mediastinal disorder—Epirubicin—pancreatic cancer	9.01e-05	0.000421	CcSEcCtD
Rasagiline—Constipation—Docetaxel—pancreatic cancer	9.01e-05	0.000421	CcSEcCtD
Rasagiline—Chills—Epirubicin—pancreatic cancer	8.97e-05	0.000419	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	8.96e-05	0.000683	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	8.89e-05	0.000677	CbGpPWpGaD
Rasagiline—Alopecia—Epirubicin—pancreatic cancer	8.84e-05	0.000413	CcSEcCtD
Rasagiline—Nausea—Gemcitabine—pancreatic cancer	8.82e-05	0.000412	CcSEcCtD
Rasagiline—Mental disorder—Epirubicin—pancreatic cancer	8.76e-05	0.00041	CcSEcCtD
Rasagiline—Malnutrition—Epirubicin—pancreatic cancer	8.71e-05	0.000407	CcSEcCtD
Rasagiline—Feeling abnormal—Docetaxel—pancreatic cancer	8.68e-05	0.000406	CcSEcCtD
Rasagiline—Nausea—Fluorouracil—pancreatic cancer	8.67e-05	0.000405	CcSEcCtD
Rasagiline—Eye disorder—Doxorubicin—pancreatic cancer	8.65e-05	0.000404	CcSEcCtD
Rasagiline—Gastrointestinal pain—Docetaxel—pancreatic cancer	8.61e-05	0.000403	CcSEcCtD
Rasagiline—Cardiac disorder—Doxorubicin—pancreatic cancer	8.59e-05	0.000401	CcSEcCtD
Rasagiline—Flatulence—Epirubicin—pancreatic cancer	8.58e-05	0.000401	CcSEcCtD
Rasagiline—Dysgeusia—Epirubicin—pancreatic cancer	8.53e-05	0.000399	CcSEcCtD
Rasagiline—Back pain—Epirubicin—pancreatic cancer	8.42e-05	0.000394	CcSEcCtD
Rasagiline—Angiopathy—Doxorubicin—pancreatic cancer	8.4e-05	0.000392	CcSEcCtD
Rasagiline—Muscle spasms—Epirubicin—pancreatic cancer	8.37e-05	0.000391	CcSEcCtD
Rasagiline—Immune system disorder—Doxorubicin—pancreatic cancer	8.36e-05	0.000391	CcSEcCtD
Rasagiline—Mediastinal disorder—Doxorubicin—pancreatic cancer	8.34e-05	0.00039	CcSEcCtD
Rasagiline—Abdominal pain—Docetaxel—pancreatic cancer	8.33e-05	0.000389	CcSEcCtD
Rasagiline—Body temperature increased—Docetaxel—pancreatic cancer	8.33e-05	0.000389	CcSEcCtD
Rasagiline—Chills—Doxorubicin—pancreatic cancer	8.3e-05	0.000388	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—BCL2L1—pancreatic cancer	8.23e-05	0.000627	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CA—pancreatic cancer	8.2e-05	0.000625	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—TSC2—pancreatic cancer	8.18e-05	0.000623	CbGpPWpGaD
Rasagiline—Alopecia—Doxorubicin—pancreatic cancer	8.18e-05	0.000382	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	8.17e-05	0.000622	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GLP1R—pancreatic cancer	8.14e-05	0.00062	CbGpPWpGaD
Rasagiline—Mental disorder—Doxorubicin—pancreatic cancer	8.11e-05	0.000379	CcSEcCtD
Rasagiline—Ill-defined disorder—Epirubicin—pancreatic cancer	8.08e-05	0.000378	CcSEcCtD
Rasagiline—Malnutrition—Doxorubicin—pancreatic cancer	8.06e-05	0.000377	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—AKT1—pancreatic cancer	8.05e-05	0.000613	CbGpPWpGaD
Rasagiline—Anaemia—Epirubicin—pancreatic cancer	8.05e-05	0.000376	CcSEcCtD
Rasagiline—MAOB—Metabolism—DPYD—pancreatic cancer	8.01e-05	0.00061	CbGpPWpGaD
Rasagiline—Agitation—Epirubicin—pancreatic cancer	8e-05	0.000374	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—SRC—pancreatic cancer	7.99e-05	0.000609	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	7.99e-05	0.000609	CbGpPWpGaD
Rasagiline—Flatulence—Doxorubicin—pancreatic cancer	7.94e-05	0.000371	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	7.9e-05	0.000602	CbGpPWpGaD
Rasagiline—Dysgeusia—Doxorubicin—pancreatic cancer	7.89e-05	0.000369	CcSEcCtD
Rasagiline—BCL2—Apoptosis—AKT1—pancreatic cancer	7.89e-05	0.000601	CbGpPWpGaD
Rasagiline—Malaise—Epirubicin—pancreatic cancer	7.85e-05	0.000367	CcSEcCtD
Rasagiline—Vertigo—Epirubicin—pancreatic cancer	7.82e-05	0.000366	CcSEcCtD
Rasagiline—Syncope—Epirubicin—pancreatic cancer	7.81e-05	0.000365	CcSEcCtD
Rasagiline—Leukopenia—Epirubicin—pancreatic cancer	7.79e-05	0.000364	CcSEcCtD
Rasagiline—Back pain—Doxorubicin—pancreatic cancer	7.79e-05	0.000364	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—pancreatic cancer	7.78e-05	0.000593	CbGpPWpGaD
Rasagiline—Hypersensitivity—Docetaxel—pancreatic cancer	7.76e-05	0.000363	CcSEcCtD
Rasagiline—Muscle spasms—Doxorubicin—pancreatic cancer	7.74e-05	0.000362	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—pancreatic cancer	7.69e-05	0.000585	CbGpPWpGaD
Rasagiline—Loss of consciousness—Epirubicin—pancreatic cancer	7.65e-05	0.000358	CcSEcCtD
Rasagiline—Cough—Epirubicin—pancreatic cancer	7.6e-05	0.000355	CcSEcCtD
Rasagiline—MAOB—Metabolism—SLC2A2—pancreatic cancer	7.6e-05	0.000579	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—HRAS—pancreatic cancer	7.59e-05	0.000578	CbGpPWpGaD
Rasagiline—Asthenia—Docetaxel—pancreatic cancer	7.56e-05	0.000353	CcSEcCtD
Rasagiline—Convulsion—Epirubicin—pancreatic cancer	7.54e-05	0.000353	CcSEcCtD
Rasagiline—Hypertension—Epirubicin—pancreatic cancer	7.52e-05	0.000351	CcSEcCtD
Rasagiline—Ill-defined disorder—Doxorubicin—pancreatic cancer	7.47e-05	0.000349	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—NFKBIA—pancreatic cancer	7.46e-05	0.000568	CbGpPWpGaD
Rasagiline—Pruritus—Docetaxel—pancreatic cancer	7.45e-05	0.000348	CcSEcCtD
Rasagiline—Anaemia—Doxorubicin—pancreatic cancer	7.45e-05	0.000348	CcSEcCtD
Rasagiline—Arthralgia—Epirubicin—pancreatic cancer	7.41e-05	0.000346	CcSEcCtD
Rasagiline—Chest pain—Epirubicin—pancreatic cancer	7.41e-05	0.000346	CcSEcCtD
Rasagiline—Agitation—Doxorubicin—pancreatic cancer	7.4e-05	0.000346	CcSEcCtD
Rasagiline—BCL2—Immune System—CD44—pancreatic cancer	7.39e-05	0.000563	CbGpPWpGaD
Rasagiline—Anxiety—Epirubicin—pancreatic cancer	7.39e-05	0.000345	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	7.36e-05	0.000344	CcSEcCtD
Rasagiline—Discomfort—Epirubicin—pancreatic cancer	7.32e-05	0.000342	CcSEcCtD
Rasagiline—Malaise—Doxorubicin—pancreatic cancer	7.26e-05	0.00034	CcSEcCtD
Rasagiline—Dry mouth—Epirubicin—pancreatic cancer	7.25e-05	0.000339	CcSEcCtD
Rasagiline—Vertigo—Doxorubicin—pancreatic cancer	7.24e-05	0.000338	CcSEcCtD
Rasagiline—Syncope—Doxorubicin—pancreatic cancer	7.22e-05	0.000338	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—pancreatic cancer	7.21e-05	0.000337	CcSEcCtD
Rasagiline—Diarrhoea—Docetaxel—pancreatic cancer	7.21e-05	0.000337	CcSEcCtD
Rasagiline—Confusional state—Epirubicin—pancreatic cancer	7.16e-05	0.000335	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—pancreatic cancer	7.16e-05	0.000545	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA1—pancreatic cancer	7.16e-05	0.000545	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	7.14e-05	0.000544	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EGF—pancreatic cancer	7.14e-05	0.000544	CbGpPWpGaD
Rasagiline—Loss of consciousness—Doxorubicin—pancreatic cancer	7.08e-05	0.000331	CcSEcCtD
Rasagiline—Infection—Epirubicin—pancreatic cancer	7.06e-05	0.00033	CcSEcCtD
Rasagiline—Cough—Doxorubicin—pancreatic cancer	7.03e-05	0.000329	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	7e-05	0.000533	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—pancreatic cancer	7e-05	0.000533	CbGpPWpGaD
Rasagiline—Shock—Epirubicin—pancreatic cancer	6.99e-05	0.000327	CcSEcCtD
Rasagiline—Convulsion—Doxorubicin—pancreatic cancer	6.98e-05	0.000326	CcSEcCtD
Rasagiline—Nervous system disorder—Epirubicin—pancreatic cancer	6.97e-05	0.000326	CcSEcCtD
Rasagiline—Dizziness—Docetaxel—pancreatic cancer	6.97e-05	0.000326	CcSEcCtD
Rasagiline—Hypertension—Doxorubicin—pancreatic cancer	6.96e-05	0.000325	CcSEcCtD
Rasagiline—Skin disorder—Epirubicin—pancreatic cancer	6.9e-05	0.000323	CcSEcCtD
Rasagiline—Hyperhidrosis—Epirubicin—pancreatic cancer	6.87e-05	0.000321	CcSEcCtD
Rasagiline—Arthralgia—Doxorubicin—pancreatic cancer	6.86e-05	0.000321	CcSEcCtD
Rasagiline—Chest pain—Doxorubicin—pancreatic cancer	6.86e-05	0.000321	CcSEcCtD
Rasagiline—Anxiety—Doxorubicin—pancreatic cancer	6.83e-05	0.000319	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	6.81e-05	0.000318	CcSEcCtD
Rasagiline—Discomfort—Doxorubicin—pancreatic cancer	6.78e-05	0.000317	CcSEcCtD
Rasagiline—Anorexia—Epirubicin—pancreatic cancer	6.77e-05	0.000317	CcSEcCtD
Rasagiline—Dry mouth—Doxorubicin—pancreatic cancer	6.71e-05	0.000314	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—AKT1—pancreatic cancer	6.7e-05	0.00051	CbGpPWpGaD
Rasagiline—Vomiting—Docetaxel—pancreatic cancer	6.7e-05	0.000313	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	6.67e-05	0.000508	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—pancreatic cancer	6.67e-05	0.000508	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	6.67e-05	0.000508	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA2—pancreatic cancer	6.66e-05	0.000507	CbGpPWpGaD
Rasagiline—Rash—Docetaxel—pancreatic cancer	6.64e-05	0.00031	CcSEcCtD
Rasagiline—Hypotension—Epirubicin—pancreatic cancer	6.64e-05	0.00031	CcSEcCtD
Rasagiline—Dermatitis—Docetaxel—pancreatic cancer	6.64e-05	0.00031	CcSEcCtD
Rasagiline—Confusional state—Doxorubicin—pancreatic cancer	6.63e-05	0.00031	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—pancreatic cancer	6.62e-05	0.000504	CbGpPWpGaD
Rasagiline—Headache—Docetaxel—pancreatic cancer	6.6e-05	0.000308	CcSEcCtD
Rasagiline—Infection—Doxorubicin—pancreatic cancer	6.53e-05	0.000305	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	6.47e-05	0.000303	CcSEcCtD
Rasagiline—Shock—Doxorubicin—pancreatic cancer	6.47e-05	0.000302	CcSEcCtD
Rasagiline—Nervous system disorder—Doxorubicin—pancreatic cancer	6.45e-05	0.000301	CcSEcCtD
Rasagiline—Insomnia—Epirubicin—pancreatic cancer	6.43e-05	0.0003	CcSEcCtD
Rasagiline—Skin disorder—Doxorubicin—pancreatic cancer	6.39e-05	0.000299	CcSEcCtD
Rasagiline—Paraesthesia—Epirubicin—pancreatic cancer	6.38e-05	0.000298	CcSEcCtD
Rasagiline—Hyperhidrosis—Doxorubicin—pancreatic cancer	6.36e-05	0.000297	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PIK3CD—pancreatic cancer	6.35e-05	0.000484	CbGpPWpGaD
Rasagiline—Dyspnoea—Epirubicin—pancreatic cancer	6.33e-05	0.000296	CcSEcCtD
Rasagiline—Somnolence—Epirubicin—pancreatic cancer	6.32e-05	0.000295	CcSEcCtD
Rasagiline—Anorexia—Doxorubicin—pancreatic cancer	6.27e-05	0.000293	CcSEcCtD
Rasagiline—Nausea—Docetaxel—pancreatic cancer	6.26e-05	0.000292	CcSEcCtD
Rasagiline—Dyspepsia—Epirubicin—pancreatic cancer	6.25e-05	0.000292	CcSEcCtD
Rasagiline—Decreased appetite—Epirubicin—pancreatic cancer	6.18e-05	0.000289	CcSEcCtD
Rasagiline—Hypotension—Doxorubicin—pancreatic cancer	6.14e-05	0.000287	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Epirubicin—pancreatic cancer	6.13e-05	0.000287	CcSEcCtD
Rasagiline—Constipation—Epirubicin—pancreatic cancer	6.08e-05	0.000284	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	5.99e-05	0.00028	CcSEcCtD
Rasagiline—Insomnia—Doxorubicin—pancreatic cancer	5.95e-05	0.000278	CcSEcCtD
Rasagiline—Paraesthesia—Doxorubicin—pancreatic cancer	5.9e-05	0.000276	CcSEcCtD
Rasagiline—MAOB—Metabolism—CD44—pancreatic cancer	5.88e-05	0.000448	CbGpPWpGaD
Rasagiline—Dyspnoea—Doxorubicin—pancreatic cancer	5.86e-05	0.000274	CcSEcCtD
Rasagiline—Feeling abnormal—Epirubicin—pancreatic cancer	5.86e-05	0.000274	CcSEcCtD
Rasagiline—Somnolence—Doxorubicin—pancreatic cancer	5.84e-05	0.000273	CcSEcCtD
Rasagiline—Gastrointestinal pain—Epirubicin—pancreatic cancer	5.81e-05	0.000272	CcSEcCtD
Rasagiline—Dyspepsia—Doxorubicin—pancreatic cancer	5.79e-05	0.000271	CcSEcCtD
Rasagiline—Decreased appetite—Doxorubicin—pancreatic cancer	5.72e-05	0.000267	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	5.68e-05	0.000265	CcSEcCtD
Rasagiline—Urticaria—Epirubicin—pancreatic cancer	5.64e-05	0.000264	CcSEcCtD
Rasagiline—MAOB—Metabolism—GCG—pancreatic cancer	5.64e-05	0.00043	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—pancreatic cancer	5.62e-05	0.000428	CbGpPWpGaD
Rasagiline—Constipation—Doxorubicin—pancreatic cancer	5.62e-05	0.000263	CcSEcCtD
Rasagiline—Abdominal pain—Epirubicin—pancreatic cancer	5.62e-05	0.000263	CcSEcCtD
Rasagiline—Body temperature increased—Epirubicin—pancreatic cancer	5.62e-05	0.000263	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PIK3CB—pancreatic cancer	5.53e-05	0.000421	CbGpPWpGaD
Rasagiline—Feeling abnormal—Doxorubicin—pancreatic cancer	5.42e-05	0.000253	CcSEcCtD
Rasagiline—Gastrointestinal pain—Doxorubicin—pancreatic cancer	5.38e-05	0.000251	CcSEcCtD
Rasagiline—MAOB—Metabolism—STK11—pancreatic cancer	5.3e-05	0.000404	CbGpPWpGaD
Rasagiline—Hypersensitivity—Epirubicin—pancreatic cancer	5.24e-05	0.000245	CcSEcCtD
Rasagiline—Urticaria—Doxorubicin—pancreatic cancer	5.22e-05	0.000244	CcSEcCtD
Rasagiline—Abdominal pain—Doxorubicin—pancreatic cancer	5.2e-05	0.000243	CcSEcCtD
Rasagiline—Body temperature increased—Doxorubicin—pancreatic cancer	5.2e-05	0.000243	CcSEcCtD
Rasagiline—Asthenia—Epirubicin—pancreatic cancer	5.1e-05	0.000238	CcSEcCtD
Rasagiline—Pruritus—Epirubicin—pancreatic cancer	5.03e-05	0.000235	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CTNNB1—pancreatic cancer	4.91e-05	0.000374	CbGpPWpGaD
Rasagiline—Diarrhoea—Epirubicin—pancreatic cancer	4.86e-05	0.000227	CcSEcCtD
Rasagiline—Hypersensitivity—Doxorubicin—pancreatic cancer	4.84e-05	0.000226	CcSEcCtD
Rasagiline—BCL2—Immune System—BCL2L1—pancreatic cancer	4.79e-05	0.000365	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PTEN—pancreatic cancer	4.78e-05	0.000364	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TSC2—pancreatic cancer	4.76e-05	0.000363	CbGpPWpGaD
Rasagiline—Asthenia—Doxorubicin—pancreatic cancer	4.72e-05	0.00022	CcSEcCtD
Rasagiline—Dizziness—Epirubicin—pancreatic cancer	4.7e-05	0.00022	CcSEcCtD
Rasagiline—Pruritus—Doxorubicin—pancreatic cancer	4.65e-05	0.000217	CcSEcCtD
Rasagiline—MAOB—Metabolism—TYMS—pancreatic cancer	4.56e-05	0.000347	CbGpPWpGaD
Rasagiline—Vomiting—Epirubicin—pancreatic cancer	4.52e-05	0.000211	CcSEcCtD
Rasagiline—Diarrhoea—Doxorubicin—pancreatic cancer	4.5e-05	0.00021	CcSEcCtD
Rasagiline—Rash—Epirubicin—pancreatic cancer	4.48e-05	0.000209	CcSEcCtD
Rasagiline—Dermatitis—Epirubicin—pancreatic cancer	4.48e-05	0.000209	CcSEcCtD
Rasagiline—Headache—Epirubicin—pancreatic cancer	4.45e-05	0.000208	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—SRC—pancreatic cancer	4.43e-05	0.000338	CbGpPWpGaD
Rasagiline—Dizziness—Doxorubicin—pancreatic cancer	4.35e-05	0.000203	CcSEcCtD
Rasagiline—BCL2—Immune System—NFKBIA—pancreatic cancer	4.34e-05	0.000331	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—NRAS—pancreatic cancer	4.27e-05	0.000325	CbGpPWpGaD
Rasagiline—Nausea—Epirubicin—pancreatic cancer	4.22e-05	0.000197	CcSEcCtD
Rasagiline—Vomiting—Doxorubicin—pancreatic cancer	4.18e-05	0.000195	CcSEcCtD
Rasagiline—BCL2—Immune System—EGF—pancreatic cancer	4.16e-05	0.000317	CbGpPWpGaD
Rasagiline—Rash—Doxorubicin—pancreatic cancer	4.15e-05	0.000194	CcSEcCtD
Rasagiline—Dermatitis—Doxorubicin—pancreatic cancer	4.14e-05	0.000194	CcSEcCtD
Rasagiline—Headache—Doxorubicin—pancreatic cancer	4.12e-05	0.000193	CcSEcCtD
Rasagiline—Nausea—Doxorubicin—pancreatic cancer	3.91e-05	0.000183	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—EGFR—pancreatic cancer	3.89e-05	0.000296	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDH1—pancreatic cancer	3.87e-05	0.000295	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—APOE—pancreatic cancer	3.71e-05	0.000283	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CD—pancreatic cancer	3.7e-05	0.000282	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KRAS—pancreatic cancer	3.67e-05	0.00028	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CA—pancreatic cancer	3.37e-05	0.000257	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CG—pancreatic cancer	3.35e-05	0.000255	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PPARG—pancreatic cancer	3.23e-05	0.000246	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CB—pancreatic cancer	3.22e-05	0.000245	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HRAS—pancreatic cancer	3.12e-05	0.000238	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PRSS1—pancreatic cancer	3.08e-05	0.000235	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CD—pancreatic cancer	2.94e-05	0.000224	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTNNB1—pancreatic cancer	2.86e-05	0.000218	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—pancreatic cancer	2.79e-05	0.000212	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT1—pancreatic cancer	2.76e-05	0.00021	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ARG2—pancreatic cancer	2.67e-05	0.000204	CbGpPWpGaD
Rasagiline—BCL2—Immune System—SRC—pancreatic cancer	2.58e-05	0.000197	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CB—pancreatic cancer	2.57e-05	0.000195	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—pancreatic cancer	2.54e-05	0.000194	CbGpPWpGaD
Rasagiline—BCL2—Immune System—STAT3—pancreatic cancer	2.49e-05	0.00019	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NRAS—pancreatic cancer	2.48e-05	0.000189	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TYMP—pancreatic cancer	2.34e-05	0.000178	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGFR—pancreatic cancer	2.26e-05	0.000172	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—pancreatic cancer	2.22e-05	0.000169	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—pancreatic cancer	2.14e-05	0.000163	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—pancreatic cancer	1.96e-05	0.00015	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.93e-05	0.000147	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GLP1R—pancreatic cancer	1.88e-05	0.000143	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—DPYD—pancreatic cancer	1.85e-05	0.000141	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—pancreatic cancer	1.82e-05	0.000138	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	1.76e-05	0.000134	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.74e-05	0.000133	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.68e-05	0.000128	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT1—pancreatic cancer	1.61e-05	0.000122	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—pancreatic cancer	1.56e-05	0.000119	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.53e-05	0.000116	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CD44—pancreatic cancer	1.36e-05	0.000104	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.33e-05	0.000102	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.32e-05	0.000101	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GCG—pancreatic cancer	1.31e-05	9.94e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKT1—pancreatic cancer	1.28e-05	9.73e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—STK11—pancreatic cancer	1.23e-05	9.35e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.15e-05	8.77e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TYMS—pancreatic cancer	1.06e-05	8.04e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—APOE—pancreatic cancer	8.59e-06	6.54e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	8.13e-06	6.19e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	7.75e-06	5.9e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPARG—pancreatic cancer	7.48e-06	5.7e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	6.81e-06	5.19e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	5.94e-06	4.52e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—pancreatic cancer	5.88e-06	4.48e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—pancreatic cancer	5.13e-06	3.91e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	3.62e-06	2.76e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKT1—pancreatic cancer	2.96e-06	2.25e-05	CbGpPWpGaD
